A Phase 1, Open-label, Single-site, Randomized, Single-dose, Three-way, Crossover Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations in Healthy Adult Participants
Latest Information Update: 03 Sep 2024
At a glance
- Drugs MYK 224 (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 03 Sep 2024 New trial record